NOVAVAX Announces Release Date of 2009 Year-End Financial Results and Investor Conference Call

ROCKVILLE, Md., March 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 year-end financial results in a press release to be issued after 8:00 a.m. local time on Friday, March 12, 2010. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. local time on Friday, March 12, 2010. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the overview of the financial results. The dial-in number for the conference call is 1 (866) 804 3550 (U.S. or Canada) or 1 (703) 639-1330 (International).  

A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the conference call will be available on Novavax's website approximately one hour after the event for 90 days and a replay of the conference call will also be available by telephone beginning March 12, 2010 at 1:00 pm through March 14, 2010 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter pass code 1412843.

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.